Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials

Lancet Oncol. 2022 Nov;23(11):e480. doi: 10.1016/S1470-2045(22)00628-3.

Author

Frédéric Fiteni¹

Affiliation

¹ Medical Oncology Department, University Hospital, 30900 Nîmes, France; University of Montpellier, 34090 Montpellier, France; UMR INSERM IDESP-Desbrest Institute of Epidemiology and Public Health, University of Montpellier, 34090 Montpellier, France. Electronic address: frederic.fiteni@chu-nimes.fr.

PMID: 36328009
DOI: 10.1016/S1470-2045(22)00628-3

No abstract available

Publication types

Letter
Comment

MeSH terms

Carcinoma, Ovarian Epithelial
Female
Humans
Ovarian Neoplasms* / drug therapy
Quality of Life*